HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound
Condition: Moderate and Severe Haemophilia
Intervention: Other: HEAD-US scoring system
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Pfizer
Not yet recruiting - verified July 2017
|
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
Condition: Hemorrhagic Hereditary Telangiectasia (HHT)
Interventions: Drug: Bevacizumab; Drug: sodium chloride 0.9%
Sponsor: Hospices Civils de Lyon
Not yet recruiting - verified July 2017
|
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Conditions: Congenital Bleeding Disorder; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Interventions: Drug: Concizumab; Drug: Eptacog alfa
Sponsor: Novo Nordisk A/S
Recruiting - verified August 2017
|
Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: turoctocog alfa
Sponsor: Novo Nordisk A/S
Not yet recruiting - verified June 2017
|
Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery
Condition: Factor 10 Deficiency
Intervention: Drug: Coagadex
Sponsor: Bio Products Laboratory
Not yet recruiting - verified July 2017
|
Factor XIII in Major Burns Coagulation
Conditions: Burns; Coagulation Disorder; Factor XIII Deficiency; Cicatrization; Endothelial Dysfunction
Intervention: Diagnostic Test: Coagulation tests
Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Not yet recruiting - verified May 2017
|
Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies
Condition: Hemophilia
Intervention: Other: Non interventional study
Sponsor: Nantes University Hospital
Recruiting - verified August 2017
|
China Registry for Genetic / Metabolic Liver Diseases
Condition: Genetic/Metabolic Liver Diseases
Intervention: Drug: Standard of care
Sponsors: Beijing Friendship Hospital; Beijing YouAn Hospital; Henan Provincial Hospital; Beijing Ditan Hospital; Hebei Medical University Third Hospital; Peking University First Hospital; Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital; Nanfang Hospital of Southern Medical University; Affiliated Hospital, Logistics University of People's Armed Police Force; Beijing Anzhen Hospital, Capital Medical University; West China Second University Hospital of Sichuan University; Jinshan Hospital of Fudan University; Fudan University
Recruiting - verified April 2017
|
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder; Haemophilia B
Interventions: Drug: N9-GP; Drug: ALPROLIX®
Sponsor: Novo Nordisk A/S
Recruiting - verified August 2017
|
Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients
Condition: Antithrombin Deficiency Type 2
Intervention: Drug: ATryn continuous infusion
Sponsors: Mayo Clinic; rEVO Biologics
Not yet recruiting - verified April 2017
|
Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
Condition: Factor VII Deficiency
Interventions: Biological: Eptacog alfa, biosimilar and reference medicinal product Novoseven; Biological: Eptacog alfa biosimilar
Sponsor: AryoGen Pharmed Co.
Recruiting - verified March 2017
|
A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
Conditions: Haemophilia A; Haemophilia B
Interventions: Drug: ELOCTA; Drug: ALPROLIX
Sponsor: Swedish Orphan Biovitrum
Recruiting - verified May 2017
|
Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
Condition: Von Willebrand Diseases
Intervention:
Sponsor: University Hospital, Lille
Not yet recruiting - verified July 2017
|
A Gene Transfer Study for Hemophilia A
Condition: Hemophilia A
Intervention: Genetic: SPK-8011
Sponsor: Spark Therapeutics
Recruiting - verified April 2017
|
Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: turoctocog alfa pegol
Sponsor: Novo Nordisk A/S
Recruiting - verified August 2017
|
Fascial Therapy in Elbow Hemophilic Arthropathy
Condition: Hemophilia
Intervention: Other: Experimental group
Sponsor: Real Fundación Victoria Eugenia
Not yet recruiting - verified January 2017
|
MRA With Feraheme in HHT
Condition: Hereditary Hemorrhagic Telangiectasia
Intervention: Procedure: Feraheme MRI/MRA
Sponsor: University of California, Los Angeles
Recruiting - verified March 2017
|
Immunmodulation in Patients With HHT
Condition: Hereditary Haemorrhagic Telangiectasia (HHT)
Intervention: Other: blood sample
Sponsor: University Hospital, Essen
Recruiting - verified December 2016
|
UK - EHL Outcomes Registry
Conditions: Hemophilia A; Hemophilia B
Intervention:
Sponsor: Royal Free Hospital NHS Foundation Trust
Not yet recruiting - verified October 2016
|
Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
Condition: Hemophilia A
Interventions: Drug: efmoroctocog alfa; Drug: Factor VIII
Sponsor: Swedish Orphan Biovitrum
Recruiting - verified February 2017
|
rVWF IN PROPHYLAXIS
Condition: Von Willebrand Disease
Interventions: Biological: von Willebrand factor (Recombinant); Biological: Antihemophilic Factor (Recombinant)
Sponsor: Baxalta US Inc.
Not yet recruiting - verified November 2016
|
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
Conditions: Congenital Bleeding Disorder; Haemophilia A
Interventions: Drug: turoctocog alfa; Drug: turoctocog alfa
Sponsor: Novo Nordisk A/S
Recruiting - verified July 2017
|
BAX 111 rVWF in Pediatrics
Condition: Von Willebrand Disease
Interventions: Biological: von Willebrand factor (Recombinant); Biological: Antihemophilic Factor (Recombinant)
Sponsor: Baxalta US Inc.
Not yet recruiting - verified October 2016
|
Graded TTCE for Post-Embolization PAVM Monitoring
Condition: Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention: Other: Transthoracic Contrast Echocardiogram
Sponsor: University of Pennsylvania
Recruiting - verified August 2017
|
Low VW Activity in Adolescent HMB
Condition: Von Willebrand Factor Deficiency
Interventions: Other: Genetic Analysis; Other: Medical Record Data Abstraction; Other: Pictorial Blood Assessment Chart (PBAC) score; Other: Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Sponsors: Baylor College of Medicine; Texas Children's Hospital; Baxalta US Inc.
Recruiting - verified July 2017
|
Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A
Condition: Hemophilia A
Interventions: Drug: Recombinant Factor VIII (50 IU/kg); Drug: Recombinant Factor VIII (On-demand treatment)
Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Recruiting - verified October 2016
|
A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children
Condition: Haemophilia
Intervention: Other: Observe the patient's condition and then change the regimen
Sponsor: Beijing Children's Hospital
Recruiting - verified December 2016
|
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT
Conditions: Hereditary Hemorrhagic Telangiectasia; Epistaxis
Interventions: Drug: Mupirocin; Other: Placebo
Sponsor: Hospital Italiano de Buenos Aires
Not yet recruiting - verified November 2016
|
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber
Conditions: Hereditary Hemorrhagic Telangiectasia; Gastrointestinal Hemorrhage; Anemia
Intervention: Drug: Octreotide LAR
Sponsors: Radboud University; St. Antonius Hospital
Recruiting - verified August 2016
|
BAX 802 in CHA With Inhibitors
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)
Sponsor: Baxalta US Inc.
Recruiting - verified April 2017
|
Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding
Condition: Von Willebrand Disease
Intervention: Other: Non interventional study
Sponsor: Nantes University Hospital
Not yet recruiting - verified June 2016
|
Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia
Condition: Haemophilia
Intervention: Other: Patient questionnaire
Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting - verified August 2016
|
The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children
Conditions: Benign Hypermobility Syndrome; Functional Constipation
Intervention:
Sponsor: Medical University of Warsaw
Recruiting - verified March 2017
|
Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
Conditions: Hypofibrinogenemia; Afibrinogenemia; Bleeding Disorders
Interventions: Drug: RiaStAP; Drug: Saline
Sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Recruiting - verified April 2017
|
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
Condition: Hemophilia A, Congenital
Intervention: Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Sponsor: Bayer
Recruiting - verified July 2017
|
World Bleeding Disorders Registry
Condition: Hemophilia A and B
Intervention:
Sponsor: World Federation of Hemophilia
Not yet recruiting - verified May 2016
|
TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia
Condition: Haemophilia A
Intervention: Other: Thrombin generation measurement.
Sponsor: Hospices Civils de Lyon
Recruiting - verified February 2017
|
Low Von Willebrand in Ireland Cohort Study
Condition: Von Willebrand Factor, Deficiency
Intervention:
Sponsor: St. James's Hospital, Ireland
Recruiting - verified May 2017
|
Investigation of the Genetics of Hematologic Diseases
Conditions: Bone Marrow Failure Syndromes; Erythrocyte Disorder; Leukocyte Disorder; Hemostasis; Blood Coagulation Disorder; Sickle Cell Disease; Dyskeratosis Congenita; Diamond-Blackfan Anemia; Congenital Thrombocytopenia; Severe Congenital Neutropenia; Fanconi Anemia
Intervention:
Sponsors: St. Jude Children's Research Hospital; Boston Children’s Hospital
Recruiting - verified September 2016
|
Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients
Conditions: Hemophilia A; Factor VIII
Intervention: Drug: Recombinant VIII factor
Sponsor: Hospital Universitario La Fe
Recruiting - verified August 2016
|
Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition: Acquired Hemophilia A
Intervention: Biological: OBIZUR
Sponsor: Baxalta US Inc.
Recruiting - verified August 2016
|
Weight-based Dosing in Hemophilia A
Condition: Hemophilia
Intervention: Drug: rFVIII
Sponsor: University of Pittsburgh
Recruiting - verified May 2017
|
Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease
Condition: Type 1 Von Willebrand Disease
Interventions: Drug: recombinant von Willebrand factor; Drug: tranexamic acid
Sponsors: University of Pittsburgh; University of North Carolina; Carnegie Mellon University; Duke University
Not yet recruiting - verified August 2017
|
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
Conditions: Hereditary Hemorrhagic Telangiectasia (HHT); Epistaxis
Interventions: Drug: Floseal; Other: Packing
Sponsors: St. Michael's Hospital, Toronto; The Ottawa Hospital
Recruiting - verified January 2017
|
Ultrasonography in Hemophilic Joint Disease and Serum Markers
Conditions: Hemophilia A; Hemophilia B; Hemarthroses
Intervention: Other: ultrasound
Sponsors: Northwell Health; National Cancer Institute (NCI); University of California, San Diego
Recruiting - verified July 2017
|
Study of Voncento® in Subjects With Von Willebrand Disease
Condition: Von Willebrand Disease
Intervention: Biological: Voncento
Sponsor: CSL Behring
Recruiting - verified August 2017
|
ATHN 2: Factor Switching Study
Condition: Hemophilia
Interventions: Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013; Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Sponsors: American Thrombosis and Hemostasis Network; Bioverativ (Biogen); Shire; CSL Behring
Recruiting - verified August 2017
|
A Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) LR769 for the Prevention of Excessive Bleeding in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX Undergoing Elective Surgery or Other Invasive Procedure
Condition: Hemophilia
Intervention: Biological: Coagulation Factor VIIa (Recombinant)
Sponsors: LFB USA, Inc.; Laboratoire français de Fractionnement et de Biotechnologies
Recruiting - verified January 2017
|
Swiss Hemophilia Registry
Condition: Hemophilia and Other Severe Bleeding Disorders
Intervention: Other: Registry
Sponsor: Swiss Hemophilia Network
Recruiting - verified March 2017
|
Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)
Condition: Von Willebrands Disease
Intervention:
Sponsors: Jonathan Roberts; Blood Center of Wisconsin
Recruiting - verified August 2016
|
Natural History Study of Factor IX Treatment and Complications
Condition: Factor IX Deficiency
Intervention: Other: Standard care with blood and urine sample collection
Sponsors: Skane University Hospital; Indiana Hemophilia and Thrombosis Center; University of Bonn; Biogen; Swedish Orphan Biovitrum
Recruiting - verified August 2017
|
A Gene Therapy Study for Hemophilia B
Condition: Hemophilia B
Intervention: Genetic: SPK-9001
Sponsors: Spark Therapeutics; Pfizer
Recruiting - verified February 2017
|
Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
Condition: Hemophilia A
Intervention: Drug: Plasma-derived FVIII/VWF concentrate
Sponsors: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Sintesi Research Srl
Recruiting - verified June 2015
|
Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease
Condition: Von Willebrand Disease
Intervention: Drug: plasma-derived FVIII/VWF concentrate Fanhdi
Sponsor: Instituto Grifols, S.A.
Recruiting - verified August 2017
|
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction
Conditions: Pulmonary Arteriovenous Malformations; Hereditary Hemorrhagic Telangiectasia; Asthma; COPD
Intervention: Other: Cardiopulmonary exercise test
Sponsor: Imperial College London
Not yet recruiting - verified April 2015
|
Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
Condition: Hemophilia
Intervention:
Sponsor: Karolinska Institutet
Recruiting - verified March 2017
|
A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa
Conditions: Hemophilia A With Inhibitors; Hemophilia B With Inhibitors
Intervention: Biological: Coagulation FVIIa (Recombinant)
Sponsors: LFB USA, Inc.; Laboratoire français de Fractionnement et de Biotechnologies
Recruiting - verified January 2017
|
A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions: Hemophilia A; Hemophilia B
Intervention: Drug: MOD-5014
Sponsor: Opko Biologics
Recruiting - verified September 2016
|
Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency
Condition: Congenital Fibrinogen Deficiency
Intervention: Biological: Octafibrin
Sponsor: Octapharma
Recruiting - verified May 2016
|
Intranasal Bevacizumab for HHT-Related Epistaxis
Conditions: HHT; Hereditary Hemorrhagic Telangiectasia; Epistaxis; Nose Bleeds; Nasal Bleeding
Interventions: Drug: Bevacizumab; Drug: Placebo (Saline)
Sponsor: Stanford University
Recruiting - verified April 2017
|
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition: Hemophilia A
Intervention: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Sponsor: Bayer
Recruiting - verified July 2017
|
To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: turoctocog alfa
Sponsor: Novo Nordisk A/S
Recruiting - verified June 2017
|
Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
Condition: Congenital Fibrinogen Deficiency
Intervention: Drug: Octafibrin
Sponsor: Octapharma
Recruiting - verified May 2016
|
Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia.
Condition: Haemophilia
Intervention:
Sponsor: Universidad de Murcia
Recruiting - verified September 2015
|
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
Conditions: Hemophilia A; Severe Hemophilia A
Intervention: Biological: rVIII‑SingleChain
Sponsor: CSL Behring
Recruiting - verified July 2017
|
Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder
Condition: Inherited Platelet Disorders
Intervention: Other: Blood collection for platelet protein samples
Sponsors: Hadassah Medical Organization; Hebrew University of Jerusalem
Not yet recruiting - verified February 2016
|
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder; Haemophilia B
Intervention: Drug: nonacog beta pegol
Sponsor: Novo Nordisk A/S
Recruiting - verified February 2017
|
ADVATE Hemophilia A Outcome Database (AHEAD)
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Sponsor: Baxalta US Inc.
Recruiting - verified March 2017
|
Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease
Conditions: Hemophilia A; Hemophilia B; Von Willebrand's Disease
Intervention:
Sponsors: Karolinska University Hospital; The Swedish Society of Medicine; Karolinska Institutet
Recruiting - verified August 2016
|
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Condition: Hemophilia B
Intervention: Biological: rIX-FP
Sponsor: CSL Behring
Recruiting - verified July 2017
|
Willebrand International Non-interventional Global Surveillance
Condition: Von Willebrand Disease
Intervention:
Sponsor: Laboratoire français de Fractionnement et de Biotechnologies
Recruiting - verified March 2016
|
Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
Condition: Haemophilia
Intervention:
Sponsor: Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus
Recruiting - verified December 2015
|
Modifiers of Disease Severity in Cerebral Cavernous Malformations
Conditions: Cavernous Angioma, Familial; Cerebral Cavernous Malformations; Cerebral Cavernous Hemangioma
Intervention:
Sponsors: University of New Mexico; University of California, San Francisco; Barrow Neurological Institute; Angioma Alliance; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2016
|
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept
Condition: Hereditary Hemorrhagic Telangiectasia
Interventions: Drug: Topical timolol maleate; Drug: placebo saline drops
Sponsors: St. Michael's Hospital, Toronto; University of California, San Francisco; The Hospital for Sick Children; University of Toronto; Sunnybrook Health Sciences Centre; Ryerson University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2017
|
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs
Conditions: Pulmonary Arteriovenous Malformations; Hereditary Hemorrhagic Telangiectasia
Interventions: Other: Cardiopulmonary exercise test; Procedure: Blood test
Sponsor: Imperial College London
Recruiting - verified October 2015
|
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder; Haemophilia A
Intervention: Drug: turoctocog alfa pegol
Sponsor: Novo Nordisk A/S
Recruiting - verified September 2016
|
Hemophilia Inhibitor Previously Untreated Patient Study
Condition: Hemophilia A
Intervention: Drug: FVIII concentrate
Sponsors: The University of Texas Health Science Center, Houston; Rho, Inc.; Baxter Healthcare Corporation
Recruiting - verified May 2016
|
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies; Inherited Disorders of Metabolism; Inherited Abnormalities of Platelets; Histiocytic Disorders; Acute Myelogenous Leukemia (AML or ANLL); Acute Lymphoblastic Leukemia (ALL); Other Acute Leukemia; Chronic Myelogenous Leukemia (CML); Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases; Other Leukemia; Hodgkin Lymphoma; Non-hodgkin Lymphoma; Multiple Myeloma/ Plasma Cell Disorder (PCD); Inherited Abnormalities of Erythrocyte Differentiation or Function; Disorders of the Immune System; Automimmune Diseases; Severe Aplastic Anemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified August 2017
|
Thrombocytopathy in Gaucher Disease Patients
Conditions: Gaucher Disease; Thrombocytopathy
Intervention:
Sponsors: Rabin Medical Center; Genzyme, a Sanofi Company
Recruiting - verified October 2016
|
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
Conditions: Thrombotic Thrombocytopenic Purpura; Congenital Thrombotic Thrombocytopenic Purpura; Familial Thrombotic Thrombocytopenic Purpura; Thrombotic Thrombocytopenic Purpura, Congenital; Upshaw-Schulman Syndrome
Intervention: Other: Observation
Sponsors: University Hospital Inselspital, Berne; Swiss National Science Foundation; Mach-Gaensslen Foundation Switzerland; Baxalta Innovations GmbH, Wien, Austria
Recruiting - verified September 2016
|
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
Condition: Hereditary Hemorrhagic Telangiectasia
Intervention:
Sponsors: St. Michael's Hospital, Toronto; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2017
|
Registry for Vascular Anomalies Associated With Coagulopathy
Conditions: Multifocal Lymphangioendotheliomatosis With Thrombocytopenia; Cutaneovisceral Angiomatosis With Thrombocytopenia; Vascular Anomaly With Thrombocytopenia; Hemangiomas
Intervention: Other: no intervention
Sponsor: Medical College of Wisconsin
Recruiting - verified March 2017
|
Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients
Condition: Von Willebrand Disease
Intervention: Biological: Alphanate SD/HT
Sponsor: Grifols Biologicals Inc.
Recruiting - verified January 2017
|
Safety, Pharmacokinetics and Efficacy of an AT-III Concentrate.
Condition: Antithrombin III Deficiency
Intervention: Drug: Plasma-derived AT-III concentrate
Sponsor: Grifols Biologicals Inc.
Recruiting - verified January 2017
|
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Condition: Glanzmann Thrombasthenia
Intervention:
Sponsors: Rockefeller University; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2016
|
Evaluation of Hemostasis in Bleeding and Thrombotic Disorders
Conditions: Blood Coagulation Disorders, Inherited; Thrombotic Disorder
Intervention:
Sponsor: The University of Texas Health Science Center, Houston
Recruiting - verified May 2016
|
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Condition: Telangiectasia, Hereditary Hemorrhagic
Intervention:
Sponsors: Imperial College London; British Heart Foundation
Recruiting - verified August 2008
|
Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
Condition: Telangiectasia, Hereditary Hemorrhagic
Intervention:
Sponsors: Imperial College London; The Margaret Hayton HHT Fund
Recruiting - verified August 2008
|
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Conditions: Albinism; Intestinal Disease; Kidney Disease; Myocardial Disease; Pulmonary Fibrosis
Intervention:
Sponsor: National Human Genome Research Institute (NHGRI)
Recruiting - verified March 9, 2017
|